Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 5497.

https://doi.org/10.1182/blood-2025-5497

Published: 2025

Journal Articles

Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 1944.

https://doi.org/10.1182/blood-2025-1944

Published: 2025

Journal Articles

Impact of chimeric antigen receptor (CAR) product cell phenotypes on clinical outcomes following treatment with obecabtagene autoleucel (obe-cel)

Benjamin Simpson, Rehan Hussain, Mohammed Banani, Karamjeet Sandhu, Michael Bishop, Aaron Logan, Ping Wang, William Day, Claire Roddie, Pierre Lao-Sirieix

Blood (2025) 146 (Supplement 1): 33.

https://doi.org/10.1182/blood-2025-33

Published: 2025

Journal Articles

Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (SLE) in the Phase I CARLYSLE study: Initial safety, preliminary efficacy, pharmacokinetics, and biomarker results

Claire Roddie, Maria Leandro, Ben Parker, Eleni Tholouli, David Jayne, Ben Uttenthal, Josefina Cortés-Hernández, Pere Barba, José Andrés Román Ivorra, Yanqing Hu, Wolfram Brugger, Silvia Basilico, Davide Germano, Ruth Pepper

Blood (2025) 146 (Supplement 1): 815.

https://doi.org/10.1182/blood-2025-815

Published: 2025

Journal Articles

CAR-T cells co-targeting BCMA and CD19 in RRMM: Results from the UKMRA Phase 1 MCARTY trial in relapsed refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4173.

https://doi.org/10.1182/blood-2025-4173

Published: 2025

Journal Articles

Chimeric antigen receptor (CAR) T-cell persistence at month 3 predicts clinical outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with obecabtagene autoleucel (obe-cel)

Claire Roddie, Jae Park, Eleni Tholouli, Karamjeet Sandhu, Paul Shaughnessy, Pere Barba, Manuel Guerreiro, Deborah Yallop, Aaron Logan, Mehrdad Abedi, Pierre Lao-Sirieix, Ping Wang, Wolfram Brugger, Bijal Shah, Anthony Hunter, Daniel Deangelo, Elias Jabbour

Blood (2025) 146 (Supplement 1): 5118.

https://doi.org/10.1182/blood-2025-5118

Published: 2025

Journal Articles

Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion

Blood (2025) 146 (14): 1664–1676.

https://doi.org/10.1182/blood.2025028790

Published: 2025

Includes: Supplemental data

Journal Articles

It’s high TIM-3 for armored CAR-T therapy for B-ALL

Alexandros Rampotas, Claire Roddie

Blood (2025) 145 (22): 2538–2540.

https://doi.org/10.1182/blood.2025028491

Published: 2025

Journal Articles

The present and future of CAR T-cell therapy for adult B-cell ALL

Alexandros Rampotas, Claire Roddie

Blood (2025) 145 (14): 1485–1497.

https://doi.org/10.1182/blood.2023022922

Published: 2025

Journal Articles

Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective

Blood (2024) 144 (Supplement 1): 4206.

https://doi.org/10.1182/blood-2024-200239

Published: 2024

Journal Articles

Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial

Claire Roddie, Jae H. Park, Paul Shaughnessy, Aaron C. Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Wolfram Brugger, Martin A Pule, Justin Shang, Elias Jabbour

Blood (2024) 144 (Supplement 1): 4845.

https://doi.org/10.1182/blood-2024-208028

Published: 2024

Journal Articles

Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)

Bijal D Shah, Jeremy Pantin, Karamjeet S Sandhu, Elias Jabbour, Jae H. Park, Paul Shaughnessy, Mehrdad Abedi, Michael R Bishop, Daniel J. DeAngelo, Wolfram Brugger, Martin Brown, Dilip Patel, Claire Roddie, Aaron C. Logan

Blood (2024) 144 (Supplement 1): 4837.

https://doi.org/10.1182/blood-2024-205694

Published: 2024

Journal Articles

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Jaime Roman Diaz, Saurabh Dahiya, Francesca Emily Sillito, Maeve O'Reilly, Kai Rejeski, Veit L. Buecklein, Marion Subklewe, Gloria Iacoboni, Pere Barba, Claire Roddie, Frederick Locke, Jay Y. Spiegel, Najla H. Al Ali, Zachary Thompson, Jongphil Kim, Rami S. Komrokji, Michael D. Jain

Blood (2024) 144 (Supplement 1): 7239.

https://doi.org/10.1182/blood-2024-201666

Published: 2024

Journal Articles

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence

Jae H. Park, Elias Jabbour, Paul Shaughnessy, Aaron C. Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Pierre Lao-Sirieix, Wolfram Brugger, Martin A Pule, Justin Shang, Claire Roddie

Blood (2024) 144 (Supplement 1): 3458.

https://doi.org/10.1182/blood-2024-201514

Published: 2024

Journal Articles

Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK

Blood (2024) 144 (Supplement 1): 2342.

https://doi.org/10.1182/blood-2024-200738

Published: 2024

Journal Articles

Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment

Alexandros Rampotas, Zoe Wong, Isaac Gannon, Camelia Benlabiod, Yuqi Shen, Charlotte Brierley, Aude-Anais Olijnik, Saif Khan, Nawshad Hayder, Gordon Weng-Kit Cheung, Marina Mitsikakou, Manuel Rodriguez-Justo, Abdullah O Khan, Adam J Mead, Jonathan Lambert, Claire Roddie, Bethan Psaila, Martin A Pule

Blood (2024) 144 (Supplement 1): 871.

https://doi.org/10.1182/blood-2024-204953

Published: 2024

Journal Articles

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Blood (2024) 144 (Supplement 1): 471.

https://doi.org/10.1182/blood-2024-205809

Published: 2024

Journal Articles

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes

Elias Jabbour, Jae H. Park, Paul Shaughnessy, Aaron C. Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Pierre Lao-Sirieix, Wolfram Brugger, Martin A Pule, Yiyun Zhang, Claire Roddie

Blood (2024) 144 (Supplement 1): 963.

https://doi.org/10.1182/blood-2024-194508

Published: 2024

Journal Articles

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 222.

https://doi.org/10.1182/blood-2023-179454

Published: 2023

Journal Articles

Development of a Phase 1 Study Evaluating the Activity of Modular CAR T for Multiple Myeloma (MCARTY) Targeting BCMA and CD19 for Improved Persistence

Blood (2023) 142 (Supplement 1): 350.

https://doi.org/10.1182/blood-2023-185085

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma

Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma

Impact of chimeric antigen receptor (CAR) product cell phenotypes on clinical outcomes following treatment with obecabtagene autoleucel (obe-cel)

Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (SLE) in the Phase I CARLYSLE study: Initial safety, preliminary efficacy, pharmacokinetics, and biomarker results

CAR-T cells co-targeting BCMA and CD19 in RRMM: Results from the UKMRA Phase 1 MCARTY trial in relapsed refractory multiple myeloma

Chimeric antigen receptor (CAR) T-cell persistence at month 3 predicts clinical outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with obecabtagene autoleucel (obe-cel)

Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion

It’s high TIM-3 for armored CAR-T therapy for B-ALL

The present and future of CAR T-cell therapy for adult B-cell ALL

Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective

Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial

Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence

Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK

Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Development of a Phase 1 Study Evaluating the Activity of Modular CAR T for Multiple Myeloma (MCARTY) Targeting BCMA and CD19 for Improved Persistence

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only